<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; creation</title>
	<atom:link href="http://www.tapanray.in/tag/creation/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Leveraging Data Science To Deliver Unique Patient-experience</title>
		<link>http://www.tapanray.in/leveraging-data-science-to-deliver-unique-patient-experience/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=leveraging-data-science-to-deliver-unique-patient-experience</link>
		<comments>http://www.tapanray.in/leveraging-data-science-to-deliver-unique-patient-experience/#comments</comments>
		<pubDate>Mon, 24 Oct 2022 00:00:22 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Actionable]]></category>
		<category><![CDATA[behavior]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[characteristics]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[creation]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[evidence]]></category>
		<category><![CDATA[excellence]]></category>
		<category><![CDATA[experience]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[insights]]></category>
		<category><![CDATA[journey]]></category>
		<category><![CDATA[Leverage]]></category>
		<category><![CDATA[marketers]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[real.world]]></category>
		<category><![CDATA[RWD]]></category>
		<category><![CDATA[RWE]]></category>
		<category><![CDATA[science]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[unique]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10719</guid>
		<description><![CDATA[“Changes in consumer behavior, many of which were accelerated by the COVID-19 pandemic, are fueling a redesign of the health ecosystem.” This finding was revealed by a recent study of the PwC’s Health Research Institute (HRI). The research provided insights about how &#8230; <a href="http://www.tapanray.in/leveraging-data-science-to-deliver-unique-patient-experience/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/leveraging-data-science-to-deliver-unique-patient-experience/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>What Have And Haven’t Changed In Pharma’s New Normal?</title>
		<link>http://www.tapanray.in/what-have-and-havent-changed-in-pharmas-new-normal/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=what-have-and-havent-changed-in-pharmas-new-normal</link>
		<comments>http://www.tapanray.in/what-have-and-havent-changed-in-pharmas-new-normal/#comments</comments>
		<pubDate>Sun, 26 Sep 2021 00:00:39 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Aduhelm]]></category>
		<category><![CDATA[analytics]]></category>
		<category><![CDATA[augmenting]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[centric]]></category>
		<category><![CDATA[changed]]></category>
		<category><![CDATA[Costs]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[creation]]></category>
		<category><![CDATA[customers]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[hits]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[marketers]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[misses]]></category>
		<category><![CDATA[modeling]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[normal]]></category>
		<category><![CDATA[Not]]></category>
		<category><![CDATA[Old]]></category>
		<category><![CDATA[outcomes]]></category>
		<category><![CDATA[Oxymoron]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[relationship]]></category>
		<category><![CDATA[repurposed]]></category>
		<category><![CDATA[sensitivity]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[support]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Telehealth]]></category>
		<category><![CDATA[transformation]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[trends]]></category>
		<category><![CDATA[triggered]]></category>
		<category><![CDATA[vaccines]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10588</guid>
		<description><![CDATA[While navigating through the challenge of disruptive changes, several pharma marketers are now focusing more on creating, connecting, and leveraging all market and customer related data, across the organization. Astute ones are using state-of-the-art tools, platforms, and techniques to gain &#8230; <a href="http://www.tapanray.in/what-have-and-havent-changed-in-pharmas-new-normal/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/what-have-and-havent-changed-in-pharmas-new-normal/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>More Challenges For Brand Launch Success In The New Normal</title>
		<link>http://www.tapanray.in/more-challenges-for-brand-launch-success-in-the-new-normal/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=more-challenges-for-brand-launch-success-in-the-new-normal</link>
		<comments>http://www.tapanray.in/more-challenges-for-brand-launch-success-in-the-new-normal/#comments</comments>
		<pubDate>Mon, 08 Feb 2021 00:00:30 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[creation]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[factors]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[insights]]></category>
		<category><![CDATA[launch]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[normal]]></category>
		<category><![CDATA[Old]]></category>
		<category><![CDATA[orchestrators]]></category>
		<category><![CDATA[outcome]]></category>
		<category><![CDATA[patient-centric]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[pivotal]]></category>
		<category><![CDATA[platforms]]></category>
		<category><![CDATA[primary care]]></category>
		<category><![CDATA[products]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reps]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[success]]></category>
		<category><![CDATA[supply-chain]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[tools]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10407</guid>
		<description><![CDATA[The drug manufacturers’ life blood to drive business growth has always been successful new product launch. However, this task has always remained a tough challenge to crack, since last so many years for various reasons. According to McKinsey &#38; Company: “About two-thirds of drug &#8230; <a href="http://www.tapanray.in/more-challenges-for-brand-launch-success-in-the-new-normal/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/more-challenges-for-brand-launch-success-in-the-new-normal/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma Branding At Tough Times</title>
		<link>http://www.tapanray.in/pharma-branding-at-tough-times/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-branding-at-tough-times</link>
		<comments>http://www.tapanray.in/pharma-branding-at-tough-times/#comments</comments>
		<pubDate>Mon, 18 Nov 2019 00:00:18 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[bias]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[branding]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[creation]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[disclosure]]></category>
		<category><![CDATA[failures]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[positive]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[Prompt]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[stakeholder]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Supply]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[times]]></category>
		<category><![CDATA[Tough]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9784</guid>
		<description><![CDATA[“About two-thirds of drug launches don’t meet expectations. Improving that record requires pharmaceutical companies to recognize the world has changed and adjust their marketing accordingly.” This appeared in an article – “The secret of successful drug launches,” published by McKinsey &#38; Company in &#8230; <a href="http://www.tapanray.in/pharma-branding-at-tough-times/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-branding-at-tough-times/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Challenge of Holistic Value Creation With Pharma M&amp;A</title>
		<link>http://www.tapanray.in/the-challenge-of-holistic-value-creation-with-pharma-ma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-challenge-of-holistic-value-creation-with-pharma-ma</link>
		<comments>http://www.tapanray.in/the-challenge-of-holistic-value-creation-with-pharma-ma/#comments</comments>
		<pubDate>Mon, 19 Aug 2019 00:00:58 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[acquisition]]></category>
		<category><![CDATA[avant-garde]]></category>
		<category><![CDATA[Broader]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[creation]]></category>
		<category><![CDATA[cycle]]></category>
		<category><![CDATA[Disruptive]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[experience]]></category>
		<category><![CDATA[greater]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[launches]]></category>
		<category><![CDATA[M&A]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[merger]]></category>
		<category><![CDATA[NCE]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[NME]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[possibilities]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[redefining]]></category>
		<category><![CDATA[takeovers]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[unique]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[value-creation]]></category>
		<category><![CDATA[virtuous]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9675</guid>
		<description><![CDATA[Two mega deals, right at the dawn of 2019 gave a flying start to Merger &#38; Acquisition (M&#38;A) activities, in search of inorganic growth, by some large pharma companies. The two biggest ones are Bristol-Myers Squibb’s (BMS) USD 74 billion buyout of &#8230; <a href="http://www.tapanray.in/the-challenge-of-holistic-value-creation-with-pharma-ma/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-challenge-of-holistic-value-creation-with-pharma-ma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Creating ‘Shared Value’ in Pharma – The Way Forward</title>
		<link>http://www.tapanray.in/creating-shared-value-in-pharma-the-way-forward/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=creating-shared-value-in-pharma-the-way-forward</link>
		<comments>http://www.tapanray.in/creating-shared-value-in-pharma-the-way-forward/#comments</comments>
		<pubDate>Mon, 30 Jul 2018 00:00:37 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[Arogya]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[corporate]]></category>
		<category><![CDATA[creation]]></category>
		<category><![CDATA[CSR]]></category>
		<category><![CDATA[Declining]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[forward]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[image]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Parivar]]></category>
		<category><![CDATA[philanthropy]]></category>
		<category><![CDATA[prices]]></category>
		<category><![CDATA[Progress]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reputation]]></category>
		<category><![CDATA[shared]]></category>
		<category><![CDATA[social responsibility]]></category>
		<category><![CDATA[social. society]]></category>
		<category><![CDATA[sustainable]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[trust]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[way]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9079</guid>
		<description><![CDATA[Many Pharmaceutical companies, both global and local, are struggling with a plethora of critical challenges. With the industry reputation diving south successful navigation through this headwind has become an onerous task, more than ever before. Under this backdrop, the article, &#8230; <a href="http://www.tapanray.in/creating-shared-value-in-pharma-the-way-forward/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/creating-shared-value-in-pharma-the-way-forward/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Rebalancing Skill Sets In Pharma Sales And Marketing</title>
		<link>http://www.tapanray.in/rebalancing-skill-sets-in-pharma-sales-and-marketing/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=rebalancing-skill-sets-in-pharma-sales-and-marketing</link>
		<comments>http://www.tapanray.in/rebalancing-skill-sets-in-pharma-sales-and-marketing/#comments</comments>
		<pubDate>Mon, 29 May 2017 00:00:33 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[automation. technology]]></category>
		<category><![CDATA[creation]]></category>
		<category><![CDATA[cyberspace]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[engagement]]></category>
		<category><![CDATA[hard]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[job]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Media]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[natives]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Rebalancing]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[sets]]></category>
		<category><![CDATA[skill]]></category>
		<category><![CDATA[Social]]></category>
		<category><![CDATA[soft]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8245</guid>
		<description><![CDATA[A disturbing trend against much needed more job creation across the world, has been well captured in a May 2016 MIT article. It concluded through several complex mathematical models that: “As more tasks performed by labor are being automated, concerns &#8230; <a href="http://www.tapanray.in/rebalancing-skill-sets-in-pharma-sales-and-marketing/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/rebalancing-skill-sets-in-pharma-sales-and-marketing/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Just 16% Of Indian Population Has Access To Free Or Partially-Free Health Care?</title>
		<link>http://www.tapanray.in/just-16-of-indian-population-has-access-to-free-or-partially-free-health-care/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=just-16-of-indian-population-has-access-to-free-or-partially-free-health-care</link>
		<comments>http://www.tapanray.in/just-16-of-indian-population-has-access-to-free-or-partially-free-health-care/#comments</comments>
		<pubDate>Mon, 05 Oct 2015 00:00:38 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[16]]></category>
		<category><![CDATA[2015]]></category>
		<category><![CDATA[2015-14]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[BRICS]]></category>
		<category><![CDATA[Budget]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[chronic]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[creation]]></category>
		<category><![CDATA[debates]]></category>
		<category><![CDATA[Dengue]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[Draft]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[Free]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[infrastructure]]></category>
		<category><![CDATA[job]]></category>
		<category><![CDATA[OECD]]></category>
		<category><![CDATA[partially]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[population]]></category>
		<category><![CDATA[private]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Rangarajan]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[status]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[TRP]]></category>
		<category><![CDATA[TV]]></category>
		<category><![CDATA[up-market]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7121</guid>
		<description><![CDATA[Is health care currently a low priority area for the Government of India? Probably yes, and thus it is worth trying to fathom it out. Besides planned frugal spending on overall public health in 2015-16, even as compared to the past &#8230; <a href="http://www.tapanray.in/just-16-of-indian-population-has-access-to-free-or-partially-free-health-care/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/just-16-of-indian-population-has-access-to-free-or-partially-free-health-care/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma FDI Debate: Highly Opinionated, Sans Assessment of Tangible Outcomes?</title>
		<link>http://www.tapanray.in/pharma-fdi-debate-highly-opinionated-sans-assessment-of-tangible-outcomes/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-fdi-debate-highly-opinionated-sans-assessment-of-tangible-outcomes</link>
		<comments>http://www.tapanray.in/pharma-fdi-debate-highly-opinionated-sans-assessment-of-tangible-outcomes/#comments</comments>
		<pubDate>Mon, 18 Nov 2013 00:00:17 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[addition]]></category>
		<category><![CDATA[assessment]]></category>
		<category><![CDATA[asset]]></category>
		<category><![CDATA[Bill]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[creation]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[direct]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[FIPB]]></category>
		<category><![CDATA[Fixed]]></category>
		<category><![CDATA[foreign]]></category>
		<category><![CDATA[ilk]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[job]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[Opinionated]]></category>
		<category><![CDATA[outcomes]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[shorn]]></category>
		<category><![CDATA[tangible]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[wage]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4217</guid>
		<description><![CDATA[In 2001, the Government of India (GoI) allowed 100 percent Foreign Direct Investments (FDI) in the pharmaceutical sector through automatic route to attract more investments for new asset creation, boost R&#38;D, new job creation and ultimately to help aligning Indian &#8230; <a href="http://www.tapanray.in/pharma-fdi-debate-highly-opinionated-sans-assessment-of-tangible-outcomes/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-fdi-debate-highly-opinionated-sans-assessment-of-tangible-outcomes/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
